(Q37142451)

English

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.

scientific article published on July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

W C Ports

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

S Khan

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

S Lan

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M Lamba

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

C Bolduc

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

R Bissonnette

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

language of work or name

0 references

publication date

1 July 2013

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

British Journal of Dermatology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

169

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

137-145

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

6 September 2017

Signal transduction pathways and transcriptional regulation in Th17 cell differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

6 September 2017

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

6 September 2017

Progress in understanding the immunopathogenesis of psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

6 September 2017

The JAK-STAT signaling pathway: input and output integration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

6 September 2017

Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

6 September 2017

Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

27 June 2018

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

3 September 2018

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

3 September 2018

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

3 September 2018

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

3 September 2018

Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: an immunohistochemical study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3761190

3 September 2018

Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Canadian guidelines for the management of plaque psoriasis: overview

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New biologic drugs get under the skin of psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23387374

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BJD.12266

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23387374%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37142451&oldid=2157069762"